Filtered By:
Condition: Cholesterol
Procedure: Coronary Angioplasty
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 178 results found since Jan 2013.
Small Dense Low-Density Lipoprotein Cholesterol: A Residual Risk for Rapid Progression of Non-Culprit Coronary Lesion in Patients with Acute Coronary Syndrome.
CONCLUSIONS: The sd-LDL-c level on treatment was significantly associated with RP of non-culprit lesions, resulting in CEs in ACS patients. On-treatment sd-LDL-c is a residual risk and aggressive reduction of sd-LDL-c might be needed to prevent CEs.
PMID: 33551393 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - February 9, 2021 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Impact of high-dose statin on cardiovascular outcomes in real-world patients with ST-elevation acute myocardial infarction
AbstractLittle is known about the impact of a high-dose statin on cardiovascular outcomes after ST-elevation acute myocardial infarction (STEMI) in real-world Japanese patients. Between July 2011 and June 2017, 1110 consecutive STEMI patients underwent primary percutaneous coronary intervention at our hospital and were discharged. A high-dose statin was administered in 117 patients (10.5%) and non-high-dose statin was administered in 947 patients (85.3%). The low-density lipoprotein cholesterol level was significantly higher in the high-dose statin group at admission (129.8 ± 44.9 vs. 110.4 ± 32.7,p < 0....
Source: Heart and Vessels - September 2, 2020 Category: Cardiology Source Type: research
Impact of nutritional index on long-term outcomes of elderly patients with coronary artery disease: sub-analysis of the SHINANO 5 year registry
In this study, patients were categorized into TCBI quartile groups. The primary endpoints were the occurre nce of major adverse cardiac and cerebrovascular events (MACCE), including all-cause death, stroke, and myocardial infarction at 5 year. The mean duration of follow up was 4.3 ± 1.7 years. The average patient age was 80.9 ± 4.3 years. MACCE was observed in 61 (40.9%) patients in the low est TCBI quartile group. Kaplan–Meier analysis demonstrated an inverse relationship between MACCE and TCBI (log-lankP < 0.001). Multivariate analysis demonstrated that low TCBI significantly predicted the inciden...
Source: Heart and Vessels - June 29, 2020 Category: Cardiology Source Type: research
Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarc-tion Patients with Primary Percutaneous Coronary Intervention.
CONCLUSION: The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach to STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel way for the treatment of STEMI patients with non-IRA disease undergoing primary PCI.
PMID: 32598255 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - June 28, 2020 Category: Biotechnology Authors: Zhao B, Li GP, Peng JJ, Ren LH, Lei LC, Ye HM, Wang ZY, Zhao S Tags: Curr Pharm Biotechnol Source Type: research
Impact of LR11 as Residual Risk on Long-Term Clinical Outcomes in Patients with Coronary Artery Disease Treated with Statins after First Percutaneous Coronary Intervention.
This study included 223 consecutive CAD patients (age, 64.5 ± 9.6 years; male, 81.2%) treated with statin after first PCI between March 2003 and December 2004 at our institution. Patients were stratified to two groups according to LR11 levels (median). Composite cardiovascular disease (CVD) endpoints that included cardiovascular death, non-fatal acute coronary syndrome and non-fatal stroke were compared between groups.The rate of CVD endpoints was significantly higher in the high LR11 group (log-rank, P = 0.0029) during the median follow-up period of 2844 days. Multivariate Cox regression analysis showed that a higher LR1...
Source: International Heart Journal - May 1, 2020 Category: Cardiology Tags: Int Heart J Source Type: research
Impact of lipoprotein(a) on long-term outcomes after percutaneous coronary intervention in patients with reduced low-density lipoprotein cholesterol.
Authors: Liu Y, Zeng Z, Yu X, Li T, Yao Y, Chen R, Zheng J
Abstract
The purpose of this study is to investigate the effect of lipoprotein(a) level on long-range prognosis after Percutaneous Coronary Intervention (PCI) in patients with low-density lipoprotein cholesterol (LDL-C) goal attainment. In this retrospective study, 350 patients in Coronary artery disease (CAD) with LDL-C less than 1.8 mmol/L were enrolled in the Guangdong Institute of Cardiovascular Diseases from January 2011 to December 2013. Follow-up was 1 year after PCI. According to the median value of the study population based on Lp(a), the patients ...
Source: Reviews in Cardiovascular Medicine - April 8, 2020 Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research
Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention.
Conclusions: Baseline serum Lp(a) can be used to predict MACEs in patients after PCI treatment, which was independent of LDL-C.
PMID: 31749864 [PubMed]
Source: Archives of Medical Science - November 23, 2019 Category: General Medicine Tags: Arch Med Sci Source Type: research
Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research
Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1
1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy
2Humanitas Clinical and Research Center-IRCCS, Milan, Italy
3Humanitas University, Milan, Italy
4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research
Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
CONCLUSION: Serum MDA-LDL levels on admission are a significant prognostic marker in patients with ACS who undergo successful PCI.
PMID: 30898480 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 17, 2019 Category: Cardiology Authors: Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, Hirohata S, Ito H Tags: J Cardiol Source Type: research
Differences in management and outcomes for men and women with ST-elevation myocardial infarction.
CONCLUSION: Women with STEMI are less likely to receive invasive management, revascularisation, or preventive medication at discharge. The reasons for these persistent differences in care require investigation.
PMID: 30025513 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - July 22, 2018 Category: General Medicine Tags: Med J Aust Source Type: research
Risk Scoring System to Assess Outcomes in Patients Treated with Contemporary Guideline-Adherent Optimal Therapies after Acute Myocardial Infarction.
CONCLUSIONS: The KorMI system would be a useful tool for predicting outcomes in survivors treated with guideline-adherent optimal therapies after AMI.
PMID: 29856143 [PubMed]
Source: Korean Circulation Journal - June 3, 2018 Category: Cardiology Tags: Korean Circ J Source Type: research
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
CONCLUSIONS: High-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in Japanese patients with stable coronary artery disease.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01042730.
PMID: 29735587 [PubMed - in process]
Source: Circulation - May 8, 2018 Category: Cardiology Authors: Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, T Tags: Circulation Source Type: research
Rationale and Design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial
Publication date: Available online 8 January 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Pedro G.M. de Barros e Silva, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, Carlos Eduardo Bosso, José Mangione, Carisi Anne Polanczyk, Amanda Sousa, Renato Kalil, Luciano de Moura Santos, Andrei C. Sposito, Rafael L. Rech, Antonio Carlos Sobral Sousa, Felipe Baldissera, Bruno Ramos Nascimento, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lucas Petri Daminani, Ligia N Laranjeira, Juliana A Borges de Oliveira, Roberto R Giraldez, Alexandre Biasi Cavalcanti, Sab...
Source: American Heart Journal - January 9, 2018 Category: Cardiology Source Type: research
Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013
CONCLUSIONSAmong CS and NCP with AMI in Ontario, similar improvements in mortality and receipt of treatments were observed between 1995 and 2013. However, compared with NCP, CS had a higher risk of mortality and heart failure. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Inna Y. Gong, Andrew T. Yan, Dennis T. Ko, Craig C. Earle, Winson Y. Cheung, Stuart Peacock, Marlous Hall, Chris P. Gale, Kelvin K. W. Chan Tags: Original Article Source Type: research
